moneyheap
KMB · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Kimberly-Clark Corp. (KMB) stock moving?
Kimberly-Clark closed its roughly $40B Kenvue acquisition on Nov 2 and reported Q3 adjusted EPS of $1.70 versus a $1.64 estimate, with sales of $4.134B slightly above the $4.126B estimate. Organic sales fell 1.3% with a roughly 270 basis point China headwind, adjusted gross margin fell 130 basis points, and the company reaffirmed its 2026 standalone outlook while reiterating $2.1B of run-rate synergies. Analysts responded with several price target increases after results: Piper Sandler to $137 (Overweight), UBS to $119 (Neutral), and BNP Paribas, Barclays and Wells Fargo to $110-112 with neutral-type ratings. Price action fits this picture: the stock fell to a 104.46 low on Nov 3 on 19.7M shares, then recovered to 111.93 on Nov 9 on 10.8M shares as targets rose, and eased to 110.76 on Nov 10. The stock now trades near the cluster of new targets, so the upside case depends on synergy delivery and China recovery, while the leverage from the $4.9B notes offering and up to $7B exchange offers adds risk.
News behind the analysis
- BNP Paribas Maintains Neutral on Kimberly-Clark, Raises Price Target to $112BNP Paribas kept its Neutral rating and raised its price target to $112 after the third-quarter results.
- Barclays Maintains Equal-Weight on Kimberly-Clark, Raises Price Target to $112Barclays kept its Equal-Weight rating and raised its price target to $112.
- Piper Sandler Maintains Overweight on Kimberly-Clark, Raises Price Target to $137Piper Sandler kept its Overweight rating and lifted its price target to $137, the highest target among the recent updates.
- Wells Fargo Maintains Equal-Weight on Kimberly-Clark, Raises Price Target to $110Wells Fargo kept its Equal-Weight rating and raised its price target to $110 after the quarterly report.
- UBS and Barclays Adjust Price Targets for Kimberly-ClarkUBS raised its target to $119 from $113 with a Neutral rating, and Barclays raised its target after the quarterly earnings report.
- Huggies Maker Kimberly-Clark Says China Diaper Allegations Were Unfounded, but Sales Damage LingersKimberly-Clark beat Q3 earnings with $1.70 EPS, closed the Kenvue deal and reaffirmed its 2026 outlook despite China sales headwinds.
- Kimberly-Clark Reports Third Quarter 2026 Financial ResultsQ3 net sales were $4.1B, organic sales fell 1.3% and adjusted EPS was $1.70, with the 2026 standalone outlook reaffirmed.
- Kimberly-Clark Q3 Adj. EPS $1.70 Beats $1.64 Estimate, Sales $4.134B Beat $4.126B EstimateAdjusted EPS and sales both came in slightly above analyst estimates for the third quarter.
- Kimberly-Clark Corporation Announces Final Results of Exchange Offers for Kenvue NotesHolders tendered most of the Kenvue notes, with tender rates from 73.9% to 98.5% across series; settlement was expected Nov 4.
- Kimberly-Clark Grants Executive Options and Appoints New Board Members Following Kenvue AcquisitionAfter the Kenvue deal, CEO Michael Hsu received premium-priced stock options and three former Kenvue directors joined the board.
About Kimberly-Clark Corp.
Kimberly-Clark is a Texas-based consumer products company that has been around for about 150 years. It is known for everyday brands like Huggies, Kleenex, Cottonelle, Scott and Kotex, and in early November 2026 it finished buying Kenvue for about $48.7 billion, which added Tylenol, Listerine, Neutrogena, Band-Aid and Johnson's Baby and made it a much bigger consumer health and wellness company.
How it makes money
The company sells branded products in supermarkets, drugstores, big-box stores and online. Before the Kenvue deal, most of its revenue came from personal care items such as diapers, baby wipes, adult incontinence and feminine care products, with consumer tissue (bath tissue, paper towels, facial tissue) and a smaller professional workplace business making up the rest. Kenvue adds over-the-counter medicines, skin care and other personal care brands, bringing combined yearly sales to roughly $32 billion. Kimberly-Clark also agreed to put much of its international tissue business into a joint venture with Suzano and plans to use the cash to pay down debt from the deal.
What usually moves KMB
- Kenvue integration and the targeted ~$2.1B in synergies
- Pulp, oil-based materials and other input costs
- Consumer volumes and pressure on pricing from store brands
- Debt levels after the acquisition and the dividend
- Tylenol litigation and regulatory headlines